Therapeutic role of Ayurvedic interventions in Amavata(Rheumatoid arthritis) with special reference to gut microbiota

Not yet recruiting

• Conditions: Other specified rheumatoid arthritis. Ayurveda Condition: AMAVATAH,

• Registration Number: CTRI/2020/10/028746
• Lead Sponsor: AMRIT GODBOLE

Brief Summary

**1.**To reflect an overview of the concept of *Amavata* vis-à-vis rheumatoid arthritis. Toreviewthe role of gut flora in the pathogenesis of rheumatoid arthritis andcharacterize the facultative aerobic bacteria’s in the gut flora in RA patientswith respect to control. To study the effect of ***Virecana Karma*** and ***Shatyadikashaya Ghana Vati*** on subjective and objectives parametersin the cases of rheumatoid arthritis. To compare the efficacyof ***VirecanaKarma*** and ***Shatyadi kashaya* *Ghana Vati***in the cases of rheumatoid arthritis. Tostudy the effect of ***Virecana Karma*** and drug over pro and anti-inflammatory markersat the baseline and at the end.

·

Detailed Description

Not available

Study Timeline

• Study Start: 2020-02-11
• Last Update Posted: 2020-10-28

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• 1.Patients of age group between 30-50 yrs willing to participate for the trial with a diagnosis of rheumatoid arthritis using the ACR 2010.
• 2.Diagnosed cases of Amavata based on symptoms and signs described in Madhav Nidana.
• 3.Patients with H/O more than 1year with established disease.
• 4.Sero positive and Seronegative both cases are included.

Exclusion Criteria

• 1.Patients not willing to participate.
• 2.Patients with a short history of less than a year.
• 3.Patients having severe deformities.
• 4.Patients of Rheumatic Arthritis, Gouty Arthritis, Infective Arthritis, Osteoarthritis.
• 5.HIV, Tuberculosis, Hypertension, D.M., and other systemic problems.
• 6.Pregnant & lactating women 7.Patients with major complications such as extra-articular manifestations are also excluded.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
IMPROVED DAS28 SCORE AND EULAR SCORE	AT THE TIME OF REGISTRATION, AT THE TIME OF 1ST FOLLOW-UP AT 30DAYS, AT 2ND FU AT 60DAYS, AT 3RD FU AT 90DAYS.

Secondary Outcome Measures

Name	Time	Method
ANTI CCP, IL 17, IL10	AT THE TIME OF REGISTRATION AND AT THE COMPLETION OF TRIAL

Trial Locations

Locations (1)

SIR SUNDERLAL HOSPITAL; 🇮🇳 Varanasi, UTTAR PRADESH, India

SIR SUNDERLAL HOSPITAL

🇮🇳Varanasi, UTTAR PRADESH, India

DR AMRIT GODBOLE

Principal investigator

07408859248

amritgodbole2@gmail.com